Please use this identifier to cite or link to this item:
Title: Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active site residues in quinidine binding
Authors: McLaughlin, Lesley A.
Paine, Mark J.L.
Kemp, Carol A.
Maréchal, Jean-Didier
Flanagan, J.U.
Ward, Clive J.
Sutcliffe, Michael J.
Roberts, Gordon C.K.
Wolf, C. Roland
First Published: 14-Sep-2005
Publisher: American Society for Biochemistry and Molecular Biology
Citation: Journal of Biological Chemistry, 2005, 280, pp.38617-38624
Abstract: We have previously shown that residues Asp301, Glu216 and Phe120 in the active site of cytochrome P450 2D6 (CYP2D6) play a key role in substrate recognition by this important drug-metabolising enzyme. We have now examined the effect of mutations of these residues on interactions of the enzyme with the prototypical CYP2D6 inhibitor, quinidine. Abolition of the negative charge on either or both residues 216 and 301 decreased quinidine inhibition of bufuralol 1'-hydroxylation and dextromethorphan O-demethylation by at least 100-fold. The apparent dissociation constants (Kd) for quinidine binding to wild type enzyme or to the Glu216Asp and Asp301Glu mutants were 0.25-0.50 μM. The amide substitutions of Glu216 or Asp301 resulted in 30 to 64-fold increases in Kd for quinidine. The double mutant Glu216Gln/Asp301Gln showed the largest decrease in quinidine affinity with a Kd of 65 μM. Changes in the mode of quinidine binding were indicated by changes in the optical difference spectra on binding. Alanine substitution of Phe120, Phe481 or Phe483 had only a minor effect on the inhibition of bufuralol 1'-hydroxylation and dextromethorphan O-demethylation, and on binding. In contrast to the wild-type enzyme, a number of the mutants studied were found to be able to metabolise quinidine. CYP2D6 Asp301Gln and Asp301Asn produced small amounts of 3-hydroxyquinidine, Asp301Ala and Asp301Phe produced O-demethylated quinidine, and Phe120Ala and Glu216Gln/Asp301Gln produced both these metabolites. Homology modelling and molecular docking were used to predict the modes of quinidine binding to wild type and mutant enzymes; these were able to rationalise the experimental observations.
DOI Link: 10.1074/jbc.M505974200
ISSN: 0021-9258
eISSN: 1083-351X
Version: Post print
Status: Peer reviewed
Type: Article
Rights: © 2005 by The American Society for Biochemistry and Molecular Biology, Inc. Deposited with reference to the publisher's archiving policy available on the SHERPA/RoMEO website. This research was originally published in Journal of Biological Chemistry. Lesley A. McLaughlin, Mark J. I. Paine, Carol A. Kemp, Jean-Didier Maréchal, Jack U. Flanagan, Clive J. Ward, Michael J. Sutcliffe, Gordon C. K. Roberts and C. Roland Wolf. Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active site residues in quinidine binding. Journal of Biological Chemistry. 2005. Vol 280: pp38617-pp.38624.
Appears in Collections:Published Articles, Dept. of Biochemistry

Files in This Item:
File Description SizeFormat 
Roberts_Quinidine.pdf5.1 MBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.